Pernilla Stridh

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Lymphocyte count polygenicity underlies dimethyl fumarate-associated lymphopenia in multiple sclerosis.

Lymphocyte count polygenicity underlies dimethyl fumarate-associated lymphopenia in multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 18, 2026

Interaction between smoking and HLA-A*02:01 in multiple sclerosis progression.

Interaction between smoking and HLA-A*02:01 in multiple sclerosis progression.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 03, 2026

Occupational Exposure to Industrial Dust and Rates of Multiple Sclerosis.

Occupational Exposure to Industrial Dust and Rates of Multiple Sclerosis.

Journal: Neurology

Published: March 13, 2026

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 03, 2026

Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis.

Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis.

Journal: Clinical & translational immunology

Published: February 26, 2026

DNA methylation mediates the multiple sclerosis onset risk associated with HHV-6 DNA positivity.

DNA methylation mediates the multiple sclerosis onset risk associated with HHV-6 DNA positivity.

Journal: Environmental epigenetics

Published: November 21, 2025

Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression.

Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression.

Journal: Journal of neuroinflammation

Published: November 05, 2025

The Multiple Sclerosis Severity Allele rs10191329A and Cognitive Function: A UK Biobank Study.

The Multiple Sclerosis Severity Allele rs10191329A and Cognitive Function: A UK Biobank Study.

Journal: Annals of clinical and translational neurology

Published: October 22, 2025

Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis.

Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: October 15, 2025

A HIF1A variant impacts long-term disability and smoldering inflammation in multiple sclerosis.

A HIF1A variant impacts long-term disability and smoldering inflammation in multiple sclerosis.

Journal: Acta neuropathologica

Published: September 02, 2025

Multiomics integration prioritizes potential drug targets for multiple sclerosis.

Multiomics integration prioritizes potential drug targets for multiple sclerosis.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 27, 2025

Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.

Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.

Journal: Journal of neurology

Published: May 27, 2025

Showing 1-12 of 64

Last Updated: 09/26/2026